Highlights d Wnt/PCP/VANGL2 are expressed in a majority of primary human rhabdomyosarcoma (RMS) 
INTRODUCTION
Continued tumor growth and relapse are driven by tumor propagating cells (TPCs) that share self-renewal properties with nontransformed stem cells (Kreso and Dick, 2014) . For example, TPCs undergo self-renewal cell divisions to produce daughter cells with identical characteristics, ultimately expanding the pool of cells capable of driving tumor growth, elevating metastasis, and evading therapy (Kreso and Dick, 2014) . TPCs can also divide asymmetrically to maintain the overall number of tumor-sustaining cells while also producing differentiated cells that have specialized functions necessary to support cancer progression and invasion Kreso and Dick, 2014) . Despite shared commonalities with normal stem cells, the molecular mechanisms regulating TPC fate specification, proliferation, and self-renewal are largely unknown, especially in pediatric sarcomas (Dela Cruz, 2013; Friedman and Gillespie, 2011) . In addition, identifying molecular markers of TPCs has been elusive in many cancer cell types, making specific characterization and therapeutic targeting difficult to achieve in the clinical setting. Yet, it is clear that TPCs drive tumor growth and are retained in a subset of patients to cause local relapse and metastasis (Dela Cruz, 2013; Kreso and Dick, 2014) . Thus, there is strong impetus to identify molecularly defined TPCs, understand the mechanisms that regulate proliferation and self-renewal, and uncover genetic vulnerabilities that can be exploited to differentiate and/or kill these tumor-sustaining cells.
The Wnt/planar cell polarity (Wnt/PCP) signaling pathway is essential during embryogenesis and for tissue homeostasis in adults (Seifert and Mlodzik, 2007) . Wnt/PCP signaling acts independent of b-catenin and is regulated by pathway-specific components such as Van Gogh (VANGL1 and VANGL2 in humans) that restrict Wnt/Frizzled activity to polarize epithelium and orient the motility of mesendodermal tissues (Peng and Axelrod, 2012; Seifert and Mlodzik, 2007) . Vangl2 is a predicted four-pass transmembrane protein, yet lacks any known receptor or enzymatic activity (Murdoch et al., 2001) . Rather protein-protein interaction domains of Vangl2 modulate downstream signaling, including the activation of Rac1 and RhoA (Schlessinger et al., 2009; Seifert and Mlodzik, 2007) . Despite well-known roles for the Wnt/ PCP pathway during development, defined roles in cancer are just now beginning to emerge. For example, oncogenic roles for non-canonical Wnt proteins have been linked to elevated cell motility, increased metastasis, and reduced patient survival in breast, liver, colon, and lung cancer (Gujral et al., 2014; Puvirajesinghe et al., 2016; Yagyu et al., 2002 ). Yet, a specific role for Wnt/PCP components in regulating TPC fate or expanding overall pools of tumor-sustaining cell types has not been established.
Rhabdomyosarcoma (RMS), a pediatric cancer of muscle, has emerged as a powerful experimental platform to assess cancer stem cell biology and to identify novel paradigms for cancer growth that extend to a wide array of malignancies Satheesha et al., 2016; Walter et al., 2011) . RMS is comprised of two main molecular subtypes. Alveolar RMS (ARMS) display characteristic genomic translocations of the PAX3-FOXO1 or PAX7-FOXO1 loci accompanied by few additional genomic changes . In contrast, RAS pathway activation is the dominant oncogenic driver in 90% of human embryonal RMS (ERMS) (Chen et al., 2013; Langenau et al., 2007; Shern et al., 2014) . Both RMS subtypes exhibit features of skeletal muscle arrested at early stages of embryonic development and display molecular characteristics consistent with a block in differentiation within the myogenic hierarchy. Importantly, TPCs have been identified in human and animal models of ERMS Langenau et al., 2007; Satheesha et al., 2016; Walter et al., 2011) . For example, we have used a fluorescent transgenic zebrafish model of kRASG12D-induced ERMS to define markers of intra-tumor heterogeneity and to isolate molecularly defined TPCs Langenau et al., 2007) . Importantly, the same developmental hierarchies controlling muscle regeneration are recapitulated in ERMS, with TPCs sharing similar molecular pathway activation and gene expression markers with activated muscle satellite stem cells. Building on these commonalities, we have identified Wnt/b-catenin, Notch, and myogenic transcription factor signaling pathways as modulators of TPC function in embryonal rhabdomyosarcoma, a role that is conserved from zebrafish to human Ignatius et al., 2017; Tenente et al., 2017) . This work highlights the power of the zebrafish model to characterize conserved stem cell pathways that drive TPC growth and maintenance that are shared in development, regeneration, and cancer.
Here, we show that VANGL2 is highly expressed in a large majority of primary human RMS and within the proliferating RMS progenitor-like cells. VANGL2 depletion led to decreased cell proliferation, reduced in vitro sphere colony formation, and differentiation of ERMS cells in vitro. Moreover, VANGL2 was required for continued xenograft growth and maintenance following engraftment of human RMS into mice. Using the kRASG12D-induced zebrafish ERMS model and fluorescent transgenic approaches to label RMS cells based on cellular differentiation status, we defined roles for Vangl2 in regulating TPC self-renewal and growth. Studies in human RMS showed that RHOA functions downstream of VANGL2 to regulate in vitro growth and sphere colony formation, a surrogate for self-renewal in ERMS. This mechanistic link between VANGL2, RHOA and TPC biology suggests mechanisms that drive RMS growth by specifically modulating a highly conserved stem cell self-renewal program.
RESULTS

VANGL2 Is Highly Expressed in Human Rhabdomyosarcoma
We previously identified a role for activated canonical Wnt/b-catenin signaling in driving differentiation of human RMS . Wnt/b-catenin signaling is normally suppressed in RMS and activation leads to TPC differentiation, reduced selfrenewal, and suppressed tumor growth both in vitro and in animal models. Given that Wnt/b-catenin signaling also drives terminal differentiation in normal muscle development and can be antagonized by non-canonical Wnt pathways (Brack et al., 2008; McCoy et al., 2011; Nemeth et al., 2007) , we investigated the possibility that alternative Wnt signaling pathway components affect RMS tumor biology.
RNA sequencing (RNA-seq data) (GEO: GSE108022) from primary patient samples described in Shern et al. (2014) was analyzed. 151 genes from the GSEAsig database (KEGG_WNT_ SIGNALING_PATHWAY) and others from the literature that represent Wnt signaling molecules or targets were selected and each was assessed for expression in human RMS subtypes. From this analysis, we identified significant upregulation of genes associated with the non-canonical Wnt/PCP signaling pathway in both fusion-negative and fusion-positive RMS (Figure 1A) . This included upregulation of Wnt ligands (WNT5B, WNT7A/B), Frizzled receptors (FZD2), and regulatory proteins (CELSR1/3, VANGL2, and PTK7) ( Figure 1A , p < 0.01). We were particularly interested in VANGL2, because Vangl proteins are essential regulators of Wnt/PCP signaling that have been well characterized in development and regeneration (von Maltzahn et al., 2012; Seifert and Mlodzik, 2007) . Moreover, unlike Wnt ligands and Frizzled receptors, Vangl proteins display minimal cross talk with the Wnt/b-catenin signaling pathway, making them useful targets to specifically interrogate Wnt/PCP signaling.
Analysis of RNA sequencing data revealed that VANGL2 was upregulated in nearly all human RMS, regardless of subtype (n = 61 of 62 fusion-negative, 23 of 23 PAX3-FOXO1 fusion-positive, and 8 of 8 PAX7-FOXO1 fusion-positive root-mean-square (RMS, R 3 SDs over the mean when compared to normal skeletal muscle, p = 0.0009 for fusion-negative, p = 0.0.0031 for PAX3-FOXO1, p = 0.0011 for PAX7-FOXO1, Student's t test comparison to normal muscle, Figure 1B ). By contrast, VANGL1 was not differentially regulated in RMS when compared with normal muscle ( Figure 1A ). VANGL2 was also highly expressed in an independent cohort of 12 primary patient samples when assessed by qRT-PCR (p < 0.05, Student's t test, Figure 1C ), and high protein levels were detected in a panel of human ERMS and ARMS cell lines ( Figure 1D ). IHC staining of pediatric RMS samples revealed VANGL2 was expressed in the majority of primary patient ERMS and ARMS (n = 43/55 ERMS and n = 14/18 ARMS, Figures 1E, 1F , S1A, and S1B). VANGL2 was detected in <10% of RMS cells in most cases (n = 39/55 ERMS and n = 13/18 ARMS, Figures 1E, 1F , S1A, and S1B), suggesting rarity of VANGL2 + cells and an underlying functional heterogeneity based on expression of this marker. VANGL2 expression was also confined to a fraction of sarcoma cells within Wilms tumor, synovial sarcoma, and desmoplastic small round cell tumor (TA-23, Stanford University Medical Centre, Figure S1C ). Together, these data prompted us to further investigate VANGL2 in the context of tumor cell growth and TPC function.
VANGL2 Affects Growth and Differentiation of Human RMS
To assess the functional significance of VANGL2 in human RMS, VANGL2 was knocked down using two short hairpin RNAs Figures 2C and 2G ). Analysis of 5-ethynyl-2'-deoxyuridine (EdU)-incorporation by flow cytometry showed significant inhibition of cell proliferation with a >7-fold reduction in S-phase cycling cells following knockdown of VANGL2 at 72 hr (Figures 2D and 2H, p < 0.0001, Student's t test) . This data showed that VANGL2 is required for human RMS tumor growth, acting predominantly through regulation of cell proliferation.
Human RD ERMS cells differentiate along a developmental hierarchy similar to that which occurs during myogenesis and regeneration (Keller and Guttridge, 2013) . To test the effect of VANGL2 loss on RMS differentiation, we next assessed myogenic regulatory factors that are expressed at specific stages of muscle differentiation. Compared to control shSCRM-infected cells, VANGL2 knockdown led to a dramatic decrease in the expression of genes associated with progenitor-like cells including PAX3, PAX7, and MET (Figure 2I , p < 0.01, Student's t test). Conversely, markers of differentiation were significantly upregulated following VANGL2 knockdown, including MCAD, MYOD, and MYOG ( Figure 2I , p < 0.01, Student's t test). Differences in PAX7 and MYOG protein expression were confirmed by western blot analysis (Figure 2E ) and immunofluorescence, with these latter experiments revealing a significant decrease in PAX7 at the cellular level in
shVL2 ( Next, we assessed a role for VANGL2 in growth and differentiation of human RMS in vivo using engraftment of control and VANGL2-depleted RD ERMS, SMSCTR ERMS, and Rh30 ARMS cells into the flanks of NOD/SCID/IL2Rg null (NSG) female mice. Cells were labeled with firefly luciferase and engrafted animals were imaged weekly to observe differences in tumor growth over time (Figures 3A, 3B, and S2) . Tumors derived from VANGL2-depleted cells displayed inhibition of growth by 28 days when monitored by total body luciferase imaging (Figures 3C -3E, p < 0.001 for RD and Rh30, p = 0.03 for SMSCTR compared to shSCRM, Student's t test). This was in contrast (1) shVL2 (2) 1 shVL2 (1) shVL2 ( In contrast to the xenograft studies using human ERMS, Rh30 ARMS tumors regrew after near complete tumor loss when assessed by luciferase bioluminescent imaging at 28 days (Figure 3E ). Knockdown and control mice had similar sized tumors at necropsy by 60 days post engraftment ( Figures S2V-S2X ). IHC staining showed that Rh30-derived tumors that grew out lacked the lentiviral vector and regained VANGL2 expression equal to or greater than shSCRM-infected control cells (Figure S2Z ). These data suggest that late-stage emergence of Rh30 ARMS resulted from growth of rare, uninfected cells introduced at the time of injection. Together, our results show that VANGL2 has important roles in regulating tumor growth and maintenance in vivo for both ERMS and ARMS.
VANGL2 Is Expressed in Proliferating Progenitor-like Cells in Human RMS
To characterize VANGL2 expression within heterogeneous cell types in RMS, human RD and Rh30 cells were assessed by immunofluorescence and co-stained with makers of proliferation and myogenic cell state. Confocal microscopy revealed that only a fraction of human RMS cells expressed VANGL2 ( Figure 4A) . Notably, the majority of VANGL2 expressing cells were actively dividing when assessed by DAPI and Ki67 staining ( Figures 4B-4K ). This was in contrast to cells expressing low levels of VANGL2, which were largely non-mitotic ( Figures  4J and 4K , p < 0.001, Student's t test). At the subcellular level, VANGL2 localized to the poles of cellular doublets in telophase ( Figures 4G-4I ), consistent with observations made during development where Vangl2 localizes to opposite ends of the axis in polarized, actively dividing satellite cells (Le Grand et al., 2009 ). Moreover, co-staining revealed that >80% of VANGL2 + cells co-expressed high levels of PAX7 ( Figures  4A-4D ), a marker of progenitor cell fate in muscle (Buckingham and Relaix, 2015 
Vangl2 Is Required for Maintenance of TPCs in Human RMS
Human RD, Ruch2, and Rh36 ERMS cells can be efficiently grown as 3D rhabdospheres, which are 100-fold more tumorigenic than adherent cells when xenografted into immunedeficient mouse models and upregulate genes associated with stemness (Walter et al., 2011) . Thus, rhabdosphere colony formation assays have become a powerful tool to estimate selfrenewal in a subset of human ERMS and to identify pathways required for TPC maintenance and growth Satheesha et al., 2016) . Western blot analysis displayed upregulation of VANGL2 in RD, Ruch2, and Rh36 rhabdospheres ( Figures  4N-4P ), suggesting possible association between VANGL2 and TPCs in human ERMS. We next assessed the requirement for VANGL2 during rhabdosphere colony formation. Specifically, control shSCRM and shVANGL2-infected RD, Ruch2, and Rh36 cells were plated at limiting cell dilution in stem cell media and the number of colonies was quantified after 10-20 days of growth ( Figures 4Q-4Y ). VANGL2 depletion led to a dramatic decrease in colony formation ( Figures 4W-4Y , p < 0.001) and culturing VANGL2 knockdown cells for more than 30 days in stem cell media failed to identify outgrowth of colonies, indicating a major requirement for VANGL2 in regulating rhabdosphere formation and in the maintenance of human RMS TPCs. Interestingly, VANGL2 was also upregulated in Rh30 ARMS cells grown in sphere media and depletion similarly led to inhibition of rhabdosphere formation ( Figure S7 ), suggesting an association between VANGL2 and sphere colony formation in RMS regardless of subtype.
Vangl2 Increases TPCs in Zebrafish ERMS
VANGL2 is uniquely expressed in human RMS progenitor-like cells, is required for maintenance of cellular identity, and is required for rhabdosphere colony formation (a surrogate for assessing TPC number and function in vitro), suggesting an important role for Vangl2 in growth and maintenance of less differentiated tumor propagating cells in human RMS. To identify oncogenic roles for Vangl2 in regulating the overall frequency of self-renewing TPCs, we next utilized a syngeneic zebrafish model of kRASG12D-induced ERMS and performed cell transplantation experiments to quantity differences in RMS that express only kRASG12D with those that transgenically co-express kRASG12D and Vangl2. Importantly, the zebrafish kRASG12D-induced ERMS shares molecular and histopathological features with human RMS and has become a valuable model to assess conserved pathways that regulate TPC function in vivo Ignatius et al., 2017; Langenau et al., 2007; Tenente et al., 2017) . Zebrafish ERMS were generated to transgenically express kRASG12D and GFP with and without Vangl2. In these studies, transgenic expression was driven by the minimal 6.5 kB rag2 promoter, which drives expression in muscle progenitors due to uncovering a myoD enhancer site . Tumor formation was observed as early as 15 days in both kRASG12D alone and kRASG12D + Vangl2 ERMS, with no overt differences in latency, penetrance, or tumor size ( Figure S4 ). H&E staining confirmed similar histology between kRASG12D alone and Vangl2 expressing ERMS ( Figures S4B and S4D ). Together, our data suggest minimal effects of Vangl2 overexpression on tumor initiation. Next, we tested the effect of Vangl2 on modulating the overall fraction of TPCs using limiting dilution cell transplantation into syngeneic zebrafish. Highly purified GFP + ERMS cells were isolated and introduced into syngeneic transplant recipient animals at limiting dilution (>90% purity and viability). Animals were followed for tumor onset for 90 days and TPC frequency quantified using the extreme limiting dilution analysis (ELDA) program.
From these experiments, we observed an increase in overall engraftment rates of ERMS cells that transgenically expressed both kRASG12D and Vangl2 (28/67 total engrafted tumors from n = 3 independent kRASG12D ERMS and 43/65 total engrafted tumors from n = 3 independent kRASG12D + Vangl2 ERMS, p = 0.004 Fisher exact test, Figures 5A-5F ). ELDA revealed a 9-fold increase in TPCs in kRASG12D + Vangl2 ERMS (Figures 5E and 5F; Table S1; p < 0.001, ELDA). Transgenic expression of Vangl2 also led to significant downregulation of markers associated with muscle differentiation including myod and myog (n = 3 tumors analyzed/genotype, Figure 5G , p < 0.01, two-way ANOVA). GFP-positive ERMS tumor cells did not have significant differences in myf5 or c-met expression ( Figure 5G ), suggesting a role for Vangl2 in regulating TPC fate by specifically inhibiting cellular differentiation.
Vangl2 Expression Identifies Self-Renewing TPCs in Zebrafish ERMS
A molecularly defined tumor-propagating cell has been identified in zebrafish ERMS Langenau et al., 2007) . This self-renewing TPC expresses satellite cell markers including myf5 and c-met and can be isolated using fluorescent protein expressed under control of muscle transgenic promoters that define specific cell states , 10 3 , and 10 2 GFP + tumor cells that co-expressed rag2:kRASG12D with or without rag2:Vangl2 (data compiled from engraftment of 3 independent tumors/genotype).
(F) Graphical analysis of extreme limiting dilution analysis (ELDA) denoting overall engraftment rates at various cell dilutions. Dotted lines represent 95% confidence intervals. Estimated tumor propagating cell number for each genotype is noted (data compiled from engraftment of 3 independent unmixed tumors/ genotype). ***p < 0.001. (G) qRT-PCR gene expression analysis performed on sorted rag2:GFP ERMS cells (independent ERMS are represented and numbered on the x axis). **p < 0.01, ***p < 0.001; n.s., not significant, two-way ANOVA. Error bars denote SD.
and mylz2:mCherry transgenic reporter lines, with GFP + / mCherry-negative cells exhibiting a >25-fold enrichment for TPCs when compared with more differentiated ERMS cells . Building on these findings, we first assessed if vangl2 was expressed in specific kRASG12D-induced ERMS cell sub-populations. As expected, based on co-expression of VANGL2 and progenitor cell markers in human RMS cells, endogenous vangl2 was highly expressed in myf5:GFP . This vangl2 promoter drives at near endogenous levels and has been previously used to dynamically visualize Wnt/PCP-dependent developmental processes in vivo (Roszko et al., 2015; Sittaramane et al., 2013) . CG1-strain syngeneic zebrafish were injected at the one cell stage with rag2:kRASG12D, rag2:GFP, and vangl2:mCherry transgenes ( Figures S6A and  S6B ). Following tumor expansion into syngeneic recipient fish ( Figures S6C and S6D ), fluorescent-labeled ERMS cell fractions were purified by FACS (n = 3 tumors/genotype, >90% viability and 80%-95% purity, Figures S6E and S6F) Figure S6K ; Table S2 (Armand et al., 2003; Goldstein et al., 2007; Hirotsu et al., 2009 Figure 6K , p < 0.001, Student's t test), consistent with the observation that these cells do not propagate ERMS and likely represent a subpopulation of non-proliferative and terminally differentiated ERMS cells Langenau et al., 2007) . Our analysis shows that myf5:GFP + /vangl2: mCherry + ERMS cells are enriched for molecular markers associated with TPCs and retain long-term self-renewal properties, further defining vangl2:mCherry as a marker of ERMS TPCs in vivo.
RHOA Regulates TPC Growth and Maintenance Downstream of VANGL2 in Human RMS
We next wanted to identify pathways downstream of VANGL2 that modulate human RMS growth and TPC function. Because Wnt/PCP signaling typically relies on activation of the Rho-family GTPases RHOA and RAC1 (Schlessinger et al., 2009 ), we first assessed their expression in adherent and 3D rhabdosphere cells. We observed increased RHOA in RD ERMS, Rh36 ERMS, and Rh30 ARMS rhabdosphere culture compared to adherent cells, coincident with upregulation of VANGL2 ( Figures 7A, 7E , and S7A). By contrast, RAC1 protein was not consistently differentially regulated across cell lines in adherent and rhabdosphere growth conditions ( Figures S7A, S7L , and S7O), suggesting a limited role for RAC1/JNK signaling in regulating TPC function.
To investigate RHOA activity downstream of VANGL2, we next assessed total RHOA and activated GTP-bound RHOA in control and VANGL2 knockdown RD, Rh36, and Rh30 cells ( Figures 7B,  7F, and S7H) . Interestingly, we observed reductions of total and activated forms of RHOA in VANGL2-depleted RMS cells ( Figures 7B, 7F , and S7H), suggesting RHOA is required downstream of VANGL2 to maintain TPCs and to elevate overall tumor propagating potential. Importantly, our results show that both RHOA activation and expression are modulated downstream of VANGL2, consistent with reports from other groups showing this duality of control by VANGL2 (Phillips et al., 2005) . By contrast, activated GTP-bound RAC1 was not consistently differentially regulated following VANGL2 knockdown ( Figures  S7J, S7M, and S7P) .
We next performed epistasis experiments using constitutively active and dominant-negative forms of RHOA and RAC1 and assessed restoration of RMS colony growth in vitro. Specifically, control and VANGL2-depleted RD ERMS, Rh36 ERMS, and Rh30 ARMS cells were infected with constitutively active (RHOAV14, RAC1V12) or dominantnegative (RHOAN19, RAC1N17) forms of human RHOA or RAC1 and assessed in rhabdosphere colony formation assays ( Figures 7C, 7G , and S7). Constitutively active RHOAV14 stimulated rhabdosphere colony formation in control cells (p < 0.01 for RD and Rh36, p = 0.033 for Rh30, Figures 7C,  7G , S7D, and S7I) while dominant-negative RHOAN19 reduced rhabdosphere formation ( Figures 7C, 7G , S7F, and S7I, p < 0.05, Student's t test). RHOAV14 also rescued rhabdosphere colony formation in VANGL2-depleted RMS cells (p < 0.001, Figures 7C, 7G , S7E, and S7I, p < 0.01, Student's t test), while dominant-negative RHOAN19 failed to rescue rhabdosphere formation ( Figures 7C, 7G , S7G, and S7I). By contrast, neither constitutively active RAC1V12 nor dominant-negative RAC1N17 could restore colony formation to VANGL2-depleted cultures ( Figures S7K, S7N, and S7Q) . Together, these data support a role for RHOA signaling downstream of VANGL2 in human RMS.
Finally, to investigate the effect of RHOA signaling on RMS TPCs and regulation of their differentiation, we next assessed myogenic factor expression in RD control, VANGL2-depleted, and RHOAV14 expressing cells. As expected, cells depleted of VANGL2 exhibited significant increases in the expression of differentiated muscle gene transcripts when compared with control cells ( Figure 7D ) while constitutively active RHOAV14 blocked differentiation and retained ERMS cells in a more undifferentiated, self-renewing TPC fate ( Figure 7D ). Together these data show that RHOA acts downstream of VANGL2 to maintain progenitorlike cell fates in ERMS and modulates the overall numbers of TPCs in human RMS. These functional studies reveal roles for a VANGL2/RHOA signaling axis in regulating sustained tumor growth through maintenance of self-renewing cell divisions.
DISCUSSION
Stem cells have the capacity to self-renew and generate more of themselves, yet these cells can also differentiate into specialized cells with unique functional characteristics. Despite a large body of literature supporting roles for canonical Wnt/b-catenin signaling in regulating stemness and cellular fate (Nusse and Clevers, 2017) , alternative Wnt signaling pathways including non-canonical Wnt/PCP signaling are less well understood. Factors associated with non-canonical Wnt signaling pathways are elevated in a large number of human cancers and are linked to poor outcome (Anastas et al., 2012; Asad et al., 2014; Gujral et al., 2014; Ma et al., 2014; Puvirajesinghe et al., 2016; Weeraratna et al., 2002; Yagyu et al., 2002; Yang et al., 2015) . VANGL proteins are required for tumor cell proliferation and growth in hepatocellular carcinoma and basal cell breast cancer (Puvirajesinghe et al., 2016; Yagyu et al., 2002) while other functional studies have focused on the role for VANGL proteins and RhoGTPases in tumor cell invasion and metastasis (Anastas et al., 2012; Asad et al., 2014; Kurayoshi et al., 2006; Ma et al., 2014; Weeraratna et al., 2002; Yang et al., 2015) . These features are consistent with known roles for this pathway in regulating migration during normal tissue morphogenesis (Seifert and Mlodzik, 2007; Simons and Mlodzik, 2008) . To date, no reports have identified specific roles for the Wnt/PCP pathway in regulating TPC growth, maintenance, or self-renewal. Our work has identified a role for Vangl2 in the maintenance of tumor progenitor cells in both human and zebrafish rhabdomyosarcoma. Moreover, our work shows that Vangl2 labels early ERMS progenitor cells and enriches for tumor propagating cells (TPCs) in both zebrafish and human, thus identifying a cross-species marker of ERMS stem-like subpopulations. Our work also revealed a requirement for VANGL2 in regulating growth, colony formation, and in vivo tumor maintenance in both human ERMS and ARMS, suggesting that conserved self-renewal properties may underlie RMS regardless of subtype and encourage future exploration of the relationship between VANGL2 and TPCs in ARMS.
We have also uncovered a major role for RHOA in regulating proliferation and maintenance of cell fate in RMS downstream of VANGL2. Despite data implicating RhoA signaling in selfrenewal of embryonic stem cells (Jaganathan et al., 2013; Lee et al., 2007; Xu et al., 2012) , mechanistic requirements for RhoA during self-renewing cancer stem cell divisions are not well understood. Given that RhoA affects myoblast proliferation through direct transcriptional regulation of Myod (Carnac et al., 1998; Dhawan and Helfman, 2004; Gopinath et al., 2007) , and our recent discovery that MYF5/MYOD is required for growth and self-renewal in human RMS (Tenente et al., 2017) , it will be important to define the relationship between VANGL2/RHOA, MYOD transcription factory family members, and proliferative programs that drive tumor growth in RMS. Wnt/PCP signaling is known to affect the orientation of cell divisions in normal tissue (Ciruna et al., 2006; Gong et al., 2004; Segalen and Bellaïche, 2009) , and it will be interesting in the future to dynamically visualize RhoA-dependent mechanisms in malignant cells to understand how orientation of proliferating TPCs may influence subsequent cell fate decisions and cancer growth in vivo.
Our work also suggests that inhibiting the VANGL2-RHOA signaling axis may provide new strategies to specifically target RMS TPCs that drive relapse and metastatic growth. Preclinical pharmacologic approaches have successfully inhibited non-canonical Wnt signaling in hepatocellular carcinoma, leading to a reduction in xenograft growth and metastasis (Gujral et al., 2014) . As a consequence, several clinical trials are currently underway to test chemical or antibody-based therapeutics designed to target Wnt/PCP in several different forms of human cancer (Daulat and Borg, 2017) . Several FDA approved small molecule inhibitors of RhoA have also been identified (Kopp et al., 2012; Lee et al., 2007) . It will be important for future experiments to test these compounds for effects on RMS self-renewal and for preclinical efficacy in suppressing xenograft growth of human RMS, in addition to suppressing more commonly RhoA-associated activities including tumor cell invasion and metastasis.
Finally, we have previously uncovered similarities in pathways that regulate stemness in normal muscle growth, regeneration, and cancer. For example, we have identified important roles for intracellular NOTCH1 in regulating TPC self-renewal and number, while activation of the Wnt/b-catenin pathway induces TPC differentiation in rhabdomyosarcoma Ignatius et al., 2017) . It has been shown that the Wnt/PCP signaling pathway plays important roles in regulating selfrenewal cell divisions in neuronal progenitor cells and muscle stem cells (Le Grand et al., 2009; Lake and Sokol, 2009 ). In regenerating muscle, Wnt7a induces the expansion of satellite cells through the non-canonical Wnt/PCP pathway (Le Grand et al., 2009) . In this setting, Wnt7a signals through the Fz7a receptor to polarize distribution of Vangl2, resulting in the expansion of satellite cells and enhanced muscle regeneration. Loss of Vangl2 also led to increased muscle differentiation in vivo (Le Grand et al., 2009 ), akin to that seen following VANGL2 knockdown in human RMS. Despite some commonalities with our studies, the downstream effectors of VANGL2 responsible for direct regulation of stem cell self-renewal in muscle have not yet been identified nor have roles for VANGL2 in regulating expansion of highly proliferative stem cell pools been established. Based on our findings and the remarkable conservation in stem cell programs between normal satellite cells and RMS, it is likely that Vangl2/RhoA will have a similar role in development and muscle regeneration.
In conclusion, we have described a role for Vangl2 in regulating the frequency and identity of tumor-sustaining cell types in RMS. Our work also suggests important and highly conserved roles for Wnt/PCP signaling in regulating cancer stem cell self-renewal across species and experimental platforms, raising the possibility that similar pathways exist in other tumor types and can be targeted therapeutically in the future (Daulat and Borg, 2017) .
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: Figure legends . Zebrafish and mice were randomly assigned to experimental groups.
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The dataset described in Shern et al. (2014) was analyzed as described in the Results section and is deposited in GEO: GSE108022.
